Class 536/28.4 - The N-hetero ring is a 1,3-diazine ring, including hydrogenated (e.g., pyrimidines, etc.)

Subclass of Class 536 - Organic compounds -- part of the class 532-570 series
Definition: Compounds wherein the N-hetero ring is a 1,3-diazine ring
No. of applications: 39
Last issue date: 02/16/2012

Application No.	Application Title	Issue Date
20120040345	2-Nitrobenzyl-Modified Ribonucleotides This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided....	02/16/2012
20110300142	USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (I...	12/08/2011
20110294754	NOVEL PHARMACEUTICAL COMPOUNDS Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders....	12/01/2011
20110293719	NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels...	12/01/2011
20110091887	METHOD FOR DETECTION OF METHYLCYTOSINE USING PHOTORESPONSIVE PROBE The present invention provides a method for detecting methylcytosine in DNA rapidly, conveniently, and with high sensitivity. The present invention relates to a method for detecting methylcytosine by using a methylcytosine photocoupling agent (a photoresponsive probe) c...	04/21/2011
20110082289	Nucleic Acid Labeling Compounds Nucleic acid labeling compounds are disclosed. The compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally o...	04/07/2011
20110082100	THERAPEUTIC SUBSTANCES THAT MODULATE GENOME METHYLATION Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expressio...	04/07/2011
20110070192	Method of preparation of novel nucleoside analogs and uses Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes. ...	03/24/2011
20110053154	2'-nitrobenzyl-modified ribonucleotides This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided....	03/03/2011
20110015145	CLADRIBINE FORMULATIONS FOR IMPROVED ORAL AND TRANSMUCOSAL DELIVERY Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine....	01/20/2011
20100166780	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity The invention relates to oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof....	07/01/2010
20100113759	PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS The present teachings relate to nucleobase, nucleoside and nucleotide compounds, methods of synthesis, and uses thereof. The present teachings provide compounds, such as nucleobase, nucleoside and/or nucleotide compounds including a propargyl linker, and methods for mak...	05/06/2010
20100112561	FLUORESCENT NUCLEOSIDE ANALOGUES Briefly described, embodiments of the present disclosure include novel fluorescent nucleoside analogs (fNAs) including a fluorescent nucleobase, selected from a purine and a pyrimidine base or analog thereof, and a modified sugar moiety that differs in structure from a ...	05/06/2010
20100087387	FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER Compounds (1, 2, 3, 4) according to the formulae shown below: (Formula 1, 2, 3, 4). For General Formula1-4:N=1-Thyminyl,9-Adeninyl,9-Guaninyl,1-Cytosinyl, 5-methyl-1-cytosinyl, 5-trifluoromethyl-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-trifluoromethyl-...	04/08/2010
20100068786	METHODS AND COMPOSITIONS FOR REVERSING P-GLYCOPROTEIN MEDICATED DRUG RESISTANCE A method for inhibiting therapeutic drug resistance within a cell over-expressing a membrane protein is provided. The method comprises synthesizing a dimeric prodrug inhibitor of a monomeric therapeutic agent; administering the dimeric prodrug inhibitor to the membrane ...	03/18/2010
20100047391	REDUCED-SALT DAIRY PRODUCT WITH IMPROVED TASTE The present invention relates to a method for preparing a dairy product with reduced sodium, wherein a yeast extract comprising at least 30% w/w 5′-ribonucleotides, on the basis of sodium chloride free dry matter, is added to a dairy composition used in the production...	02/25/2010
20090318556	BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, β-thymidine, taurine, xanthine, xanthosine, 2′-deoxyuridine, 2′-deoxycytidine, 2′...	12/24/2009
20090170724	Labelled nucleotides Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group....	07/02/2009
20090169504	Compounds and Pharmaceutical compositions for the treatment of Viral infections Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination wi...	07/02/2009
20090124797	NOVEL SYNTHESIS OF BETA-NUCLEOSIDES This invention relates to a process of stereoselectively synthesizing β-nucleoside, e.g., 2′-deoxy-2,2′-difluorocytidine....	05/14/2009
20090118222	NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT A novel pyrimidine nucleoside compound represented by the following formula (1): (wherein one of X and Y represents a cyano group, and the other represents a hydrogen atom; one of R¹and R²	05/07/2009
20090099105	Content dependent inhibitors of cytidine deaminases and uses thereof This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof....	04/16/2009
20090075931	DEUTERIUM-ENRICHED CAPECITABINE The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same....	03/19/2009
20090075342	Metabolic profile directed aptamer medicinal chemistry The present invention provides materials and methods for enhancing aptamers. More specifically, the materials and methods of the present invention are directed toward the modification of aptamers by the identification of one or more cleavage sites, and introduction of a...	03/19/2009
20090068751	Methods of Labelling Polynucleotides with Dibenzorhodamine Dyes Dibenzorhodamine compounds having the structure are disclosed, including nitrogen- and aryl-substituted forms thereof. In addition, two intermediates useful for synthesizing such compounds are disclosed, a fi...	03/12/2009
20080300398	2'-FLUORONUCLEOSIDES A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:	12/04/2008
20080293668	[5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [...	11/27/2008
20080280850	Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or...	11/13/2008
20070275912	Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA vi...	11/29/2007
20070270374	2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl...	11/22/2007
20070232562	Antiviral nucleosides Compounds having the formula I wherein R¹is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates u...	10/04/2007
20070232798	Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom Oligonucleotide analogs are disclosed having pyrimidine monomeric sub-units therein that are modified at the 2′ and 5′ positions. Monomeric sub-units having these modifications may be further modified at the 2′ position. Improved processes for the synthesis of 2�...	10/04/2007
20070208170	INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES The present invention provides a highly stereoselective, simple and economical glycosylation process for preparation of β-anomer enriched 2¹-deoxy-2¹,2¹-D-ribofuranosyl difluoronucleosides of formula (II), and physiologically acceptable...	09/06/2007
20070191598	Process for Preparing Gemcitabine and Associated Intermediates The present invention provides processes for preparing novel chemical substances that are useful as intermediates in the preparation of gemcitabine and processes for preparing gemcitabine therewith. Exemplary intermediates include mixtures of D-erythro and D-threo (3R- ...	08/16/2007
20070190530	Method for bisulfite treatment The invention is related to the detection of a methylated cytosine in a nucleic acid wherein guanidinium hydrogen sulfite is used for the preparation of a solution containing guanidinium ions and sulfite ions and subsequent modification of the nucleic acid. Thereby, a n...	08/16/2007
20070015914	Stereoselective synthesis of beta-nucleosides This invention relates to a process for stereoselectively preparing a nucleoside of the following formula: wherein R₃, R₄, and B are defined herein. The process includes reacting a furanose compound with a nucleobase in the presence of a ...	01/18/2007
20060286065	Releasable polymeric conjugates based on aliphatic biodegradable linkers Activated polymeric bicine derivatives such as as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed. ...	12/21/2006
20050153308	Method and materials for polyamine catalyzed bisulfite conversion of cytosine to uracil The invention provides methods and materials for conversion of cytosine to uracil. In some embodiments, a nucleic acid, such as gDNA, is reacted with bisulfite and a polyamine catalyst, such as a triamine or tetra-amine. Optionally, the bisulfite comprises magnesium bis...	07/14/2005
20050131224	Method for preparing radiolabeled thymidine The invention is a novel method and precursor for preparing radiolabeled nucleosides. In particular, the invention is useful for preparing 3′-[¹⁸F]fluorothymidine. The method uses an enol group that is attached to the 2-position on the pyrimidine ring. The ...	06/16/2005

PatentStorm

Did You Know...

PatentStorm News

Class 536/28.4 - The N-hetero ring is a 1,3-diazine ring, including hydrogenated (e.g., pyrimidines, etc.)